NCT05642585View on ClinicalTrials.gov

A Study of Single-dose MY008211A in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

June 4, 2023

Study Completion Date

June 4, 2023

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

MY008211A tablets

Single oral

DRUG

Placebo

Single oral

Trial Locations (1)

410011

The Third Hospital of Changsha, Changsha

All Listed Sponsors

lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY